At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 60 target
Drug / intervention
SAL-0951 tablets 4mg +1 moredrug
Likely dose
SAL-0951 tablets 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06737081Phase 2RecruitingUpdate OverdueUpdated 18mo ago · Completion was 6mo agoEnrollment Stalled
Update Overdue
A Parallel, Open-label Phase II Clinical Study of Enarodustat (SAL-0951) Tablets in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies
In Brief
A Phase 2 clinical trial evaluating SAL-0951 tablets 4mg and SAL-0951 tablets 5mg for Anemia. Currently recruiting, targeting 60 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in the treatment of chemotherapy-induced anemia (CIA) in patients with non-myeloid malignancies
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesChina
Collaborators--
Timeline
Phase 2RecruitingOverdue
20252026
Enrollment StartSep 2024
First PostedDec 2024
Primary CompletionDec 2025
Study CompletionJun 2026
TodayJul 2026
First PostedDec 17, 2024
Enrollment StartSep 14, 2024
Primary CompletionDec 31, 2025
Study CompletionJun 30, 2026
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 1.5 years ago
Interventions
SAL-0951 tablets 4mgdrug
initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
SAL-0951 tablets 5mgdrug
initial phase：5mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks